|
WO2020117135A1
|
|
A process for preparation of 1h-pyrazolo[3,4-d] pyrimidine derivatives
|
|
WO2020072008A1
|
|
Novel solid dispersions of selinexor
|
|
WO2019135101A1
|
|
A process for preparation of 5-(2-(substituted-amino)-1-hydroxyethyl)-8-(substituted-oxy) quinolin-2(1h)-one
|
|
WO2019053491A1
|
|
Crystalline solid forms of benidipine hcl and methods of preparing same
|
|
EP3419607A1
|
|
Stable formulations of fingolimod
|
|
WO2016157064A1
|
|
Stable ricobendazole formulations
|
|
EP3042892A1
|
|
Amorphisation of levosalbutamol tartrate
|
|
EP2799065A1
|
|
Levodopa carbidopa entacapone pharmaceutical formulations
|
|
EP2749557A1
|
|
Process for preparation of alpha polymorph of imatinib mesylate from IPA and THF solvate forms of imatinib mesylate
|
|
EP2749271A1
|
|
Optimized manufacturing method and pharmaceutical formulation of imatinib
|
|
EP2749553A1
|
|
Process for preparation of enantiomerically pure S-(+)-N, N-dimethyl-a-[2-(naphthalenyloxy)ethyl] benzenemethanamine
|
|
EP2749269A1
|
|
Process for the preparation of adsorbates of imatinib
|
|
EP2609910A1
|
|
Formulations of eprotirome
|
|
EP2609909A1
|
|
Mozavaptan formulations
|
|
EP2609912A1
|
|
Pharmaceutical combination of fingolimod and nabiximols
|
|
EP2604596A1
|
|
Polymorphs of imatinib
|
|
EP2604995A1
|
|
Content extractor for metered dose inhalers
|
|
EP2591768A1
|
|
Single unit dosage formulations of sevelamer and fat soluble vitamins and surface active agents
|
|
EP2526925A1
|
|
A dose adjustable oral pump spray or aerosol spray containing memantine
|
|
EP2526931A1
|
|
Wet granulation methods of cetyl myristate and/or cetyl palmitate
|
